ACR Convergence 2022

November 10-14, 2022. Philadelphia, PA.

View by Number View by Title View Sessions

View by Date

Monday, November 14, 2022

3:00PM-4:00PM: Abstract Number: 2186

Cellular and Humoral Responses Following SARS-CoV-2 mRNA Vaccination in Patients on PD-1 Immunotherapy with irAEs

Abstracts: T Cell Biology and Targets in Autoimmune and Inflammatory Disease

3:00PM-4:30PM: Abstract Number: 2203

Changes in Tophus Composition During Urate-Lowering Therapy: A Dual Energy CT Study

Abstracts: Imaging of Rheumatic Diseases

3:00PM-4:00PM: Abstract Number: 2190

Characterizing Compensatory Cognitive Strategy Use in People with Systemic Sclerosis

Abstracts: Cognition and Behavior in RA and Systemic Sclerosis

3:00PM-4:30PM: Abstract Number: 2232

Clinical Features and Long-term Outcomes of Patients with Systemic Polyarteritis Nodosa Diagnosed Since 2005: Data from 196 Patients

Abstracts: Vasculitis – Non-ANCA-Associated and Related Disorders II

3:00PM-4:00PM: Abstract Number: 2187

Decision-Making Around Vaccination and Other Public Health Measures During the COVID-19 Pandemic: Experiences of Individuals with Rheumatoid Arthritis

Abstracts: Cognition and Behavior in RA and Systemic Sclerosis

3:00PM-4:30PM: Abstract Number: 2214

Deep Immune Profiling Uncovers Novel Associations with Variable Clinical Phenotypes of Multisystem Inflammatory Syndrome in Children (MIS-C)

Abstracts: Pediatric Rheumatology – Clinical II: JIA

3:00PM-4:00PM: Abstract Number: 2185

Development of a Novel Regulatory T Cell-Based Therapy for Patients with Rheumatoid Arthritis

Abstracts: T Cell Biology and Targets in Autoimmune and Inflammatory Disease

3:00PM-4:30PM: Abstract Number: 2228

Development of the Takayasu’s Arteritis Integrated Disease Activity Index

Abstracts: Vasculitis – Non-ANCA-Associated and Related Disorders II

3:00PM-4:30PM: Abstract Number: 2208

Diagnostic Performance of Hip Ultrasound in Calcium Pyrophosphate Deposition Disease

Abstracts: Imaging of Rheumatic Diseases

3:00PM-4:30PM: Abstract Number: 2217

Disease Response in Rheumatoid Arthritis Across 4 Biologic Therapies Associates with Improvement in Paraoxonase-1 Activity

Abstracts: RA – Treatment III: Comorbidities and Consequences

3:00PM-4:30PM: Abstract Number: 2231

Earlier and More Aggressive Treatment of Major Organ Involvement with Biologics May Prevent Relapses or Further New Organ Involvement in Behçet’s Disease

Abstracts: Vasculitis – Non-ANCA-Associated and Related Disorders II

3:00PM-4:30PM: Abstract Number: 2209

Efficacy of Secukinumab in Enthesitis-related Arthritis and Juvenile Psoriatic Arthritis Subtypes of Juvenile Idiopathic Arthritis: Results from a Randomized, Phase 3 Study

Abstracts: Pediatric Rheumatology – Clinical II: JIA

3:00PM-4:30PM: Abstract Number: 2218

Frailty Is Associated with Serious Infections in Biologic and Targeted-synthetic DMARD Treated Patients with Rheumatoid Arthritis

Abstracts: RA – Treatment III: Comorbidities and Consequences

3:00PM-4:30PM: Abstract Number: 2224

Genes Causative of Primary Immunodeficiency Are Risk Factors for and Over-expressed in Systemic Lupus Erythematosus

Abstracts: SLE – Diagnosis, Manifestations, and Outcomes III: Genetic Factors

3:00PM-4:00PM: Abstract Number: 2181

Gut Microbe-derived Short-Chain Fatty Acids Regulate Arthritis and Myositis During Chikungunya Virus Infection

Abstracts: RA – Animal Models

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].